Short follicular phase of stimulation following corifollitropin alfa or daily recombinant FSH treatment does not compromise clinical outcome: a retrospective analysis of the Engage trial
Language English Country Netherlands Media print-electronic
Document type Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
24581989
DOI
10.1016/j.rbmo.2013.12.009
PII: S1472-6483(14)00010-8
Knihovny.cz E-resources
- Keywords
- corifollitropin alfa, infertility, ongoing pregnancy rate, ovarian stimulation, recombinant FSH, short follicular phase,
- MeSH
- Time Factors MeSH
- Chorionic Gonadotropin administration & dosage MeSH
- Adult MeSH
- Double-Blind Method MeSH
- Follicular Phase physiology MeSH
- Follicle Stimulating Hormone, Human administration & dosage MeSH
- Follicle Stimulating Hormone administration & dosage MeSH
- Ovulation Induction methods MeSH
- Humans MeSH
- Recombinant Proteins administration & dosage MeSH
- Retrospective Studies MeSH
- Pregnancy MeSH
- Pregnancy Rate MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Multicenter Study MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
- Names of Substances
- Chorionic Gonadotropin MeSH
- Follicle Stimulating Hormone, Human MeSH
- Follicle Stimulating Hormone MeSH
- follicle stimulating hormone, human, with HCG C-terminal peptide MeSH Browser
- Recombinant Proteins MeSH
To evaluate whether a short follicular phase of ovarian stimulation compromises the chance of pregnancy, subjects from a double-blind, randomized trial treated with a single dose of corifollitropin alfa (n=756) or daily recombinant FSH (n=750) were categorized as early responders if three follicles ≥17 mm were reached and human chorionic gonadotrophin (HCG) was administered prior to or on stimulation day 8, and as normal responders if three follicles ≥17 mm were reached and HCG was administered after stimulation day 8. In the corifollitropin alfa and recombinant FSH groups, 23.2% and 29.1%, respectively, were early responders (P=0.01). Regardless of the treatment group, the initial ovarian response was higher in early responders, but with two extra days of stimulation, the number and size of follicles on the day of HCG in the normal responders was similar to those of the early responders. The number of oocytes was similar in both response groups following corifollitropin alfa treatment (13.6 versus 14.5) and recombinant FSH treatment (12.8, both groups). The ongoing pregnancy rates were comparable for early and normal responders regardless of the treatment group, supporting successful outcome following a stimulation period of only 1 week.
Center for Reproductive Medicine Hurley Medical Center Flint MI USA
Department of Reproductive Medicine and Gynecology University Medical Center Utrecht The Netherlands
References provided by Crossref.org
